Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
1985-6-3
|
| pubmed:abstractText |
Two new classes of actinomycin D analogues, tetracyclic "reverse" analogues and a tricyclic "symmetrical" analogue of actinomycin D, are reported. These analogues bind to DNA and the binding does not occur by an intercalation mechanism. The analogues inhibit the synthesis of DNA and RNA in P388 tumor cells and the growth of CCRF-CEM cells in vitro at nanomolar concentrations. The tetracyclic "reverse" analogues, which are structurally related to the previously reported actinomycin D oxazolyl analogues, are metabolized in the presence of rat hepatic microsomes and tumor cell homogenates. The metabolism takes place with the loss of the oxazole ring; thus the "reverse" analogues produce a major metabolite which is the "symmetrical" analogue; the actinomycin oxazolyl analogues generate 7-hydroxyactinomycin D. Further, the microsomes activate the analogues to free-radical states which catalyze the production of superoxide as shown by stimulation of epinephrine oxidation and also indicated by electron paramagnetic resonance studies. The "symmetrical" and "reverse" analogues also demonstrate very high activities in these systems. In in vivo studies using P388/S, P388/ADR leukemia, and B16 melanoma in mice, the analogues showed increased activity and superior therapeutic index values, in comparison to actinomycin D.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/DNA,
http://linkedlifedata.com/resource/pubmed/chemical/DNA, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Dactinomycin,
http://linkedlifedata.com/resource/pubmed/chemical/Free Radicals,
http://linkedlifedata.com/resource/pubmed/chemical/NADP,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Superoxides
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
0022-2623
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
28
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
620-8
|
| pubmed:dateRevised |
2008-11-21
|
| pubmed:meshHeading |
pubmed-meshheading:2985784-Animals,
pubmed-meshheading:2985784-Biotransformation,
pubmed-meshheading:2985784-Cattle,
pubmed-meshheading:2985784-Chemistry, Physical,
pubmed-meshheading:2985784-DNA,
pubmed-meshheading:2985784-DNA, Neoplasm,
pubmed-meshheading:2985784-Dactinomycin,
pubmed-meshheading:2985784-Free Radicals,
pubmed-meshheading:2985784-Leukemia P388,
pubmed-meshheading:2985784-Male,
pubmed-meshheading:2985784-Melanoma,
pubmed-meshheading:2985784-Mice,
pubmed-meshheading:2985784-Microsomes, Liver,
pubmed-meshheading:2985784-NADP,
pubmed-meshheading:2985784-Oxidation-Reduction,
pubmed-meshheading:2985784-Physicochemical Phenomena,
pubmed-meshheading:2985784-RNA, Neoplasm,
pubmed-meshheading:2985784-Rats,
pubmed-meshheading:2985784-Sonication,
pubmed-meshheading:2985784-Superoxides
|
| pubmed:year |
1985
|
| pubmed:articleTitle |
"Reverse" and "symmetrical" analogues of actinomycin D: metabolic activation and in vitro and in vivo tumor growth inhibitory activities.
|
| pubmed:publicationType |
Journal Article,
In Vitro,
Research Support, Non-U.S. Gov't
|